REVIEW ARTICLE
CAQ Corner: Cardiovascular and pulmonary evaluation of liver transplantation candidates: What you need to know for the board exam
Manhal Izzy,
Hilary M. DuBrock,
Corresponding Author
Manhal Izzy
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
Correspondence
Manhal Izzy, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, Nashville, TN 37232, USA.
Email: [email protected]
Search for more papers by this authorHilary M. DuBrock
Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorManhal Izzy,
Hilary M. DuBrock,
Corresponding Author
Manhal Izzy
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
Correspondence
Manhal Izzy, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, Nashville, TN 37232, USA.
Email: [email protected]
Search for more papers by this authorHilary M. DuBrock
Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorFirst published: 26 April 2022
Earn CME and MOC for this article: www.wileyhealthlearning.com/aasld.aspx
CONFLICT OF INTEREST
Nothing to report.
REFERENCES
- 1Barman PM, VanWagner LB. Cardiac risk assessment in liver transplant candidates: current controversies and future directions. Hepatology. 2021; 73: 2564–76.
- 2Khurmi NS, Chang YH, Eric Steidley D, Singer AL, Hewitt WR, Reddy KS, et al. Hospitalizations for cardiovascular disease after liver transplantation in the United States. Liver Transpl. 2018; 24: 1398–410.
- 3Aghaulor B, VanWagner LB. Cardiac and pulmonary vascular risk stratification in liver transplantation. Clin Liver Dis. 2021; 25: 157–77.
- 4Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014; 59: 1144–65.
- 5Xiao J, Yong JN, Ng CH, Syn N, Lim WH, Tan DJH, et al. A meta-analysis and systematic review on the global prevalence, risk factors, and outcomes of coronary artery disease in liver transplantation recipients. Liver Transpl. 2021; 28: 689–99.
- 6Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation. 2012; 126: 617–63.
- 7VanWagner LB, Harinstein ME, Runo JR, Darling C, Serper M, Hall S, et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. Am J Transplant. 2018; 18: 30–42.
- 8Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, et al. Cirrhotic cardiomyopathy predicts post-transplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transpl. 2021; 27: 876–86.
- 9Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, et al. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology. 2020; 71: 334–45.
- 10Dowsley TF, Bayne DB, Langnas AN, Dumitru I, Windle JR, Porter TR, et al. Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation. Transplantation. 2012; 94: 646–51.
- 11Alper I, Ulukaya S, Demir F, Kilic M. Effects of cardiac valve dysfunction on perioperative management of liver transplantation. Transplant Proc. 2009; 41: 1722–6.
- 12Ahmed T, Misumida N, Grigorian A, Tarantini G, Messerli AW. Transcatheter interventions for valvular heart diseases in liver cirrhosis patients. Trends Cardiovasc Med. 2021. https://doi.org/10.1016/j.tcm.2021.12.014
10.1016/j.tcm.2021.12.014 Google Scholar
- 13Danad I, Raijmakers PG, Driessen RS, Leipsic J, Raju R, Naoum C, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. JAMA Cardiol. 2017; 2: 1100–7.
- 14Moon YJ, Kwon HM, Jung KW, Jeong HW, Park YS, Jun IG, et al. Risk stratification of myocardial injury after liver transplantation in patients with computed tomographic coronary angiography-diagnosed coronary artery disease. Am J Transplant. 2019; 19: 2053–66.
- 15Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018; 391: 41–50.
- 16Wood A, Eghtesad B, Menon KVN, Fares M, Tong MZ, Sharma V, et al. Safety and outcomes of combined liver transplantation and cardiac surgery in cirrhosis. Ann Thorac Surg. 2021; 111: 62–8.
- 17Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol. 2013; 59: 367–74.
- 18Kia L, Cuttica MJ, Yang A, Donnan EN, Whitsett M, Singhvi A, et al. The utility of pulmonary function testing in predicting outcomes following liver transplantation. Liver Transpl. 2016; 22: 805–11.
- 19DuBrock HM, Krowka MJ, Krok K, Forde K, Mottram C, Scanlon P, et al. Prevalence and impact of restrictive lung disease in liver transplant candidates. Liver Transpl. 2020; 26: 989–99.
- 20Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, et al. International liver transplant society practice guidelines: diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016; 100: 1440–52.
- 21Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008; 135: 1168–75.
- 22Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53:1801913.
- 23Deroo R, Trepo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al. Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology. 2020; 72: 1701–16.
- 24Forde KA, Fallon MB, Krowka MJ, Sprys M, Goldberg DS, Krok KL, et al. Pulse oximetry is insensitive for detection of hepatopulmonary syndrome in patients evaluated for liver transplantation. Hepatology. 2019; 69: 270–81.
- 25Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl. 2013; 19: 602–10.
- 26Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005–12.
- 27Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014; 145: 723–8.
